… –approved proteasomal inhibitor bortezomib (BTZ) has … its dependence on proteasome
inhibition has been conclusively … its reliance on proteasome inhibition for these actions in vivo …

… proteasome inhibitor in DLBCL cell lines. Bortezomib and MG132 were used as proteasome
inhibitors… myelodysplastic symdrome, non-small cell lung cancer and breast cancer (32–36). …

… is a proteasome inhibitor targeting proteasome activators … , which associates with bortezomib
resistance and inferior outcome … Differential expressed genes (DEGs) after I3MO treatment …

… efficacy of proteasome inhibitors such as bortezomib in solid … MCF7 is a breast cancer
cell line derived from pleural … cell line is a well-differentiated human pancreatic carcinoma …

… Osteocytes are terminally differentiated cells of the OB … the abovementioned effects of
proteasome inhibition, bortezomib … breast cancer cell lines treated with bortezomib revealed that …

… TNBCs are enriched for poorly differentiated tumor initiating cells, … proteasome inhibitor,
bortezomib (Btz), we also tested the effect of Btz on mitochondrial respiration in SUM159PT cells. …

… are independent from their proteasome inhibition, as demonstrated in adult mice dorsal root
ganglia primary sensory neurons, and, first, we demonstrate, in a cell free model, that BTZ is …

… , deeper proteasome inhibition may overcome bortezomib’s … In terms of other PIs, differential
effects of oral ixazomib and … of triple negative breast cancer cell lines to bortezomib (…

… peutic agent against cells of solid tumors (eg, prostate and breast cancer), and has … the
proteasome inhibitor bortezomib. We first decided to investigate whether there was a differential …

… proteasome inhibitors, ranging from the first-generation bortezomib to the latest second-generation
inhibitors … various types of tumors, including human breast cancer cells, at nanomolar …